Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chikungunya virus vaccine - Themis Bioscience

Next Previous
Drug Profile

Chikungunya virus vaccine - Themis Bioscience

Alternative Names: Measles-vectored Chikungunya vaccine; MV-CHIK; MV-CHIK/DP; V-184

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Themis Bioscience
  • Developer National Institute of Allergy and Infectious Diseases; Themis Bioscience
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chikungunya virus infections

Most Recent Events

  • 30 Nov 2022 Chikungunya virus vaccine is still in phase II trials for Chikungunya virus infection (Prevention)(Merck pipeline, November 2022)
  • 13 May 2021 Themis Bioscience completes a phase II trial in Chikungunya virus infection (Prevention) in Puerto Rico (IM (NCT03807843)
  • 28 Jun 2020 No recent reports of development identified for phase-I development in Chikungunya-virus-infections(Prevention) in USA (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top